Unintentional Weight Loss and Cancer: A Prospective Trial of Patient-centered Weight Track
Unintentional weight loss (UWL) is commonly associated with a wide variety of diseases and there is still no valid diagnostic pathway for evaluating UWL. When detecting UWL coupled with GRAIL Galleri testing, (an investigational pan-cancer early detection test), it is thought that there is a greater positive predictive
| Condition(s) | Unintended Weight Loss |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Unintentional weight loss (UWL) is commonly associated with a wide variety of diseases and there is still no valid diagnostic pathway for evaluating UWL. When detecting UWL coupled with GRAIL Galleri testing, (an investigational pan-cancer early detection test), it is thought that there is a greater positive predictive value in detecting malignancies. This study aims to test the potential synergistic effects of UWL detection and GRAIL usage to detect malignancy at an even earlier rate. UWL will be measured using weekly weight tracking. |
| Who can participate | Inclusion Criteria: * Age range: from 40 to 80 years * Access to a device (cellphone, computer, tablet) that is compatible with the Fitbit Aria Air smart scale utilized in this study * Willing to comply with all study procedures and be available for the duration of the study * Subjects must be mentally competent and must have the ability to understand and the willingness to sign a written informed consent document * Subjects must speak English to maximize chance of understanding the trial rational and study procedures Exclusion Criteria: * Active cancer diagnosis - current diagnosis, currently undergoing cancer treatment, or concluded cancer treatments within 3 years * Actively trying to lose weight with medications or bariatric surgery * Pregnant |
| Ages | 40 Years to 80 Years |
| Sex | All |
| Lead sponsor | Case Comprehensive Cancer Center |
| Locations | Cleveland, Ohio, United States |
| Start date | 2023-05-05 |
| NCT ID | NCT05481697 |
| Official listing | https://clinicaltrials.gov/study/NCT05481697 |